Direct oral anticoagulants (DOACs) are indicated by the European Medicines Agency and
US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial …

Abstract Purpose of Review To review the clinical evidence underlying the efficacy and
safety of the use of direct oral anticoagulants (DOACs) for the treatment of patients with …

Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF), which, according to the American College of …

Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other
Than Significant Mitral Stenosis and Mechanical Valves | Circulation Science Volunteer Warning …

Objective: To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non–Food and Drug Administration approved indications. Data Sources: Articles from …

Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in
patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more …

Introduction Patients with atrial fibrillation (AF) and concomitant moderate-to-severe mitral
stenosis (MS) are listed as a contraindicated population to direct oral anticoagulant (DOAC) …

Atrial fibrillation patients with concomitant valvulopathies constitute a group with high
thromboembolic risk and should be treated with oral anticoagulation. There is good …